Shorla Drug Patent Portfolio
Shorla owns 2 orange book drugs protected by 3 US patents Given below is the list of Shorla's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11975013 | Stable formulations comprising thiotepa | 16 Aug, 2041 | Active |
| US11129833 | Methotrexate formulation | 28 Oct, 2035 | Active |
| US11771701 | Methotrexate formulation | 29 Oct, 2034 | Active |
Latest Legal Activities on Shorla's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Shorla.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 22 Jan, 2024 | US11771701 |
|
Email Notification
Critical
| 22 Jan, 2024 | US11771701 |
|
Email Notification
Critical
| 22 Jan, 2024 | US11129833 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 22 Jan, 2024 | US11129833 |
|
Recordation of Patent Grant Mailed
Critical
| 03 Oct, 2023 | US11771701 |
| Mail Patent eGrant Notification | 03 Oct, 2023 | US11771701 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 03 Oct, 2023 | US11771701 |
| Patent eGrant Notification | 03 Oct, 2023 | US11771701 |
| Recordation of Patent eGrant | 03 Oct, 2023 | US11771701 |
|
Email Notification
Critical
| 03 Oct, 2023 | US11771701 |
|
Email Notification
Critical
| 15 Sep, 2023 | US11771701 |
|
Issue Notification Mailed
Critical
| 13 Sep, 2023 | US11771701 |
|
Application Is Considered Ready for Issue
Critical
| 05 Sep, 2023 | US11771701 |
| Dispatch to FDC | 05 Sep, 2023 | US11771701 |
|
Issue Fee Payment Received
Critical
| 25 Aug, 2023 | US11771701 |
Shorla's Family Patents
Shorla Drug List
Given below is the complete list of Shorla's drugs and the patents protecting them.
1. Jylamvo
Jylamvo is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11129833 | Methotrexate formulation |
28 Oct, 2035
(10 years from now)
| Active |
| US11771701 | Methotrexate formulation |
29 Oct, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jylamvo's drug page
2. Tepylute
Tepylute is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11975013 | Stable formulations comprising thiotepa |
16 Aug, 2041
(16 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tepylute's drug page